Maple Capital Management, Inc. Biogen Inc. Transaction History

Maple Capital Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$282.99 - $369.05 $189,603 - $247,263	-670 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$259.0 - $414.71 $173,530 - $277,855	670 New	670 $229,000
Q2 2020 Aug 12, 2020	SELL	$258.66 - $342.55 $202,013 - $267,531	-781 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$220.06 - $304.07 $18,485 - $25,541	-84 Reduced 9.71%	781 $232,000
Q3 2018 Nov 14, 2018	SELL	$293.51 - $383.83 $1,174 - $1,535	-4 Reduced 0.46%	865 $0
Q2 2018 Aug 08, 2018	SELL	$257.52 - $306.91 $3,862 - $4,603	-15 Reduced 1.7%	869 $0
Q1 2018 May 11, 2018	SELL	$260.13 - $367.91 $2,601 - $3,679	-10 Reduced 1.12%	884 $0
Q4 2017 Feb 15, 2018	BUY	$307.64 - $344.58 $7,691 - $8,614	25 Added 2.88%	894 $285,000
Q3 2017 Nov 03, 2017	BUY	$281.15 - $329.69 $244,319 - $286,500	869	869 $272,000

1,022

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Maple Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Maple Capital Management, Inc. with notifications on news.